Director Todd C. Davis purchased 35,445 shares of Pelthos Therapeutics at $27.80 on June 11, 2026, marking the largest insider purchase in the company's history. This significant capital commitment by a director suggests confidence in the company's pipeline and recent commercial traction.
Price context
The stock is currently trading at $27.50, up 4.6% over the last five days despite a 124.31% gain over the past year, yet it remains 49.35% below its 52-week high of $54.29.
Catalysts to watch
- •The trade itself is a catalyst, as it represents the largest insider purchase in the company's history.
- •Upcoming catalysts include the Q1 2026 earnings report on May 14, 2026, which saw revenue and EPS beat estimates by 12.03% and 22.75% respectively.
- •Management highlighted commercial traction for ZELSUVMI and plans to add two additional pediatric-focused dermatology products during an investor interview on March 29, 2026.
Risks
- •Recent Q1 2026 earnings reports noted a net loss and rising expenses despite revenue growth.
- •The stock carries a high beta of 3.196, indicating significant volatility relative to the market.
AI-generated context from public data. Not investment advice. Verify before trading.